Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns "Buy" Rating from Chardan Capital

Key Points

• Chardan Capital reaffirmed its “Buy” rating on Arrowhead Pharmaceuticals and set a $115 price target, implying roughly 97% upside from the cited $58.37 share price. Analysts overall assign the stock a “Moderate Buy” consensus rating with an average target of $98.31.
• Arrowhead’s latest quarterly results included a loss of $1.36 per share, worse than the $1.23 consensus estimate, although revenue of $75.25 million exceeded expectations and rose 171% year over year.
• Investor interest is also being driven by early ARO-MAPT data showing tau reductions of up to 73% in healthy volunteers, but the Alzheimer’s findings remain preliminary and require validation in patients.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report)'s stock had its "buy" rating restated by stock analysts at Chardan Capital in a research note issued to investors on Thursday, Benzinga reports. They currently have a $115.00 target price on the biotechnology company's stock. Chardan Capital's price objective indicates a potential upside of 97.02% from the stock's previous close.

A number of other equities research analysts have also weighed in on the stock. Citigroup began coverage on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 8th. They issued a "buy" rating and a $108.00 price objective for the company. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 27th. Piper Sandler restated an "overweight" rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Leerink Partners upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a "market perform" rating in a report on Wednesday, June 17th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $98.31.

Arrowhead Pharmaceuticals Trading Up 0.4%

Shares of ARWR opened at $58.37 on Thursday. The firm has a market cap of $8.22 billion, a price-to-earnings ratio of -25.94 and a beta of 1.29. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. Arrowhead Pharmaceuticals has a fifty-two week low of $36.02 and a fifty-two week high of $95.49. The firm has a 50 day moving average price of $76.71 and a 200-day moving average price of $75.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The company's revenue was up 171.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.26) earnings per share. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Adeoye Olukotun sold 2,000 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the transaction, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. This represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael Perry sold 11,600 shares of the company's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares of the company's stock, valued at $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ARWR. BlackRock Inc. bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth about $1,208,838,000. Baker BROS. Advisors LP increased its stake in shares of Arrowhead Pharmaceuticals by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company's stock worth $144,441,000 after acquiring an additional 504,883 shares in the last quarter. Siren L.L.C. increased its stake in shares of Arrowhead Pharmaceuticals by 7.7% in the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company's stock worth $101,290,000 after acquiring an additional 115,000 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Arrowhead Pharmaceuticals by 12.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company's stock worth $90,119,000 after acquiring an additional 156,544 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its stake in shares of Arrowhead Pharmaceuticals by 23.8% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,273,266 shares of the biotechnology company's stock worth $79,612,000 after acquiring an additional 244,530 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: ARO-MAPT produced deep and durable reductions in tau, reaching as much as 73% in healthy volunteers. Arrowhead said the study marks the first successful clinical demonstration of its platform achieving substantial target-gene knockdown in the brain, a potentially important milestone for its central-nervous-system pipeline. Arrowhead ARO-MAPT interim clinical data
• Positive Sentiment: The Alzheimer’s candidate’s ability to cross the blood-brain barrier and reduce tau is driving investor enthusiasm, although the current evidence is limited to an early-stage study in healthy volunteers. Positive ARO-MAPT Phase 1/2a data
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $120 price target, implying substantial upside from the provided $58.37 reference price. The target reflects increased optimism around ARO-MAPT and Arrowhead’s broader CNS pipeline.
• Neutral Sentiment: Management discussed ARO-MAPT’s interim findings and the TRiM CNS delivery platform, highlighting potential pipeline expansion into additional neurological diseases. Arrowhead ARO-MAPT and TRiM discussion
• Negative Sentiment: The data remain preliminary and were generated in healthy volunteers, so they do not yet establish that ARO-MAPT improves cognition or slows Alzheimer’s progression. Further clinical testing and confirmation in patients will be necessary.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.